Colorectal cancer incidence is increasing in people aged 50-54 and younger than 50, and a prior decrease in incidence is flattening in individuals aged 55-74.
In locally advanced rectal cancer, primary surgery followed by selective adjuvant chemoradiation was inferior to standard neoadjuvant preoperative chemoradiation followed by surgery.
The consensus recommendations address key areas in rectal cancer trial design, including the need to incorporate endpoints important to patients and establish the optimal use of neoadjuvant therapy.
Every single rectal cancer patient with a certain mutation entered remission after receiving the experimental immunotherapy drug in a small clinical trial.